https://www.selleckchem.com/pr....oducts/geneticin-g41
ppreciable results in combating SARS-COV-2. Thus, Nagaraadi Kashayam, a classical formulation can be a trial candidate for conducting further clinical trial.The outbreak of SARS-CoV-2 started in Hubei province of China in December 2019 and rapidly spread all over the world. It has infected more than 7 million people worldwide and has pushed half of the world in a state of lockdown. There is an urgent unmet need of interventions both for prevention and treatment of this disease and more than 500 clinical trials are ongoing
Like
Comment
Share
